MERZ on the Move: Days After Ulthera Acquisition, Company Announces Plans for New Retinoid Therapy
Days after Ulthera acquisition, company announces plans to develop new Retinoid Therapy with Brickell Biotech.
Days after Ulthera acquisition, company announces plans to develop new Retinoid Therapy with Brickell Biotech.
Study results presented at EADV 2025 show nearly half of initial complete responders maintained clearance over four years.